Literature DB >> 9045965

Prognostic value of the doubling time of serum C-reactive protein and alkaline phosphatase levels in primary bone and soft tissue tumors.

K Yudoh1, H Matsui, M Kamanori, K Ohmori, T Yasuda, H Tsuji, S Tatezaki.   

Abstract

We investigated the clinical relevance of doubling time (DT) of serum laboratory data obtained in routine clinical examination of patients with primary bone and soft tissue tumors, in comparison with major clinical and pathological parameters (age at presentation, sex, tumor size, location, clinical stage and histologic grade) by uni- and multivariate analyses. In 64 patients with primary bone and soft tissue tumors (primary bone tumors: 39, primary soft tissue tumors: 25) and 68 cancer patients, the pretreatment DT values of serum C-reactive protein (CRP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), calcium (Ca), phosphate (P) levels were measured, as well as the erythrocyte sedimentation rate (ESR: mm/60 min); these values were then compared with overall survival, local recurrence-free survival and metastasis-free survival. Only DT of CRP and ALP (CRP-DT, ALP-DT) were found to be correlated with disease outcome in patients with primary bone and soft tissue tumors. In cancer patients, only CRP-DT showed a relation with clinical stage and histologic grade, but the ALP-DT in patients with bone metastasis was significantly shorter than that in patients with metastases at other sites or in those with no metastasis. Among all tumor patients, those with bone metastasis showed the shortest ALP-DT compared with those with lung, liver and brain metastasis. Univariate analysis showed that shorter CRP-DT and ALP-DT are associated with poor overall survival, and the development of local recurrence and metastasis. These findings suggest that pretreatment CRP- and ALP-DT could be additional prognostic parameters for disease outcome in patients with primary malignant bone and soft tissue tumors. However, in multivariate analysis, only ALP-DT, but not CRP-DT, was an independent prognostic parameter for these disease outcomes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9045965      PMCID: PMC5921019          DOI: 10.1111/j.1349-7006.1996.tb03145.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  23 in total

1.  Serum ferritin: a tumor marker for renal cell carcinoma.

Authors:  A Essen; H Ozen; A Ayhan; A Ergen; C Tasar; F Remzi
Journal:  J Urol       Date:  1991-06       Impact factor: 7.450

Review 2.  Prognosis in osteogenic sarcoma.

Authors:  M D Lockshin; I T Higgins
Journal:  Clin Orthop Relat Res       Date:  1968 May-Jun       Impact factor: 4.176

3.  Prognosis in renal carcinoma.

Authors:  L E Böttiger
Journal:  Cancer       Date:  1970-10       Impact factor: 6.860

4.  Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  High-molecular-mass alkaline phosphatase in serum and bile: physical properties and relationship with other high-molecular-mass enzymes.

Authors:  P M Crofton; A F Smith
Journal:  Clin Chem       Date:  1981-06       Impact factor: 8.327

6.  Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy.

Authors:  G Bacci; P Picci; S Ferrari; M Orlandi; P Ruggieri; R Casadei; A Ferraro; R Biagini; A Battistini
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

Authors:  D M Vigushin; M B Pepys; P N Hawkins
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

9.  Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas.

Authors:  Y Umehara; T Kimura; M Yoshida; N Oba; Y Harada
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

10.  Doubling time of circulating cea and its relation to survival of patients with recurrent colorectal cancer.

Authors:  H J Staab; F A Anderer; A Hornung; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

View more
  2 in total

Review 1.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

Review 2.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.